title: Isolation and characterization of proliferative, migratory and multidrug-resistant             endometrial carcinoma-initiating cells from human type II endometrial carcinoma             cell lines.
abstract: Although the highly proliferative, migratory and multidrug resistant phenotype             of human type II endometrial carcinoma (EC) is well characterized, improved clinical             treatments have not yet been developed. In this study, CD44 and CD133 were used             as markers to screen, isolate and enrich carcinoma-initiating cells (CICs) from             the human type II EC cell lines KLE and ANCA3. Using flow cytometry, we identified             a subpopulation of KLE and ANCA3 cells which express high levels of both CD44             and CD133 on the cell membrane. CD44+/CD133+ EC-CICs exhibited high levels of             stemness marker genes, and possessed a higher migratory and invasive ability than             CD44-/CD133- endometrial carcinoma cells (EC-CCs). CD44+/CD133+ EC-CICs were also             more resistant to growth inhibition induced by the chemotherapeutic drugs cisplatin             and paclitaxel. Additionally, CD44+/CD133+ EC-CICs readily established tumors             in vivo in a relatively short time. In conclusion, CD44+/CD133+ cells possessing             the characteristics of CICs can be reliably sorted from KLE and ANCA3 human type II             EC cell lines, and represent a valuable model for studying cancer cell physiology             and multidrug resistance. Further characterization of CD44+/CD133+ KLE and ANCA3             cells may have a profound impact on the selection of individual treatment strategies,             clinical outcomes and design of the next generation of chemotherapeutic agents             for type II EC.
authors.affiliation: International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University, Shanghai 200030, PR China. enidou@yahoo.com.cn
authors.forename: Yongtao
authors.initials: Y
authors.lastname: Gao
authors.forename: Te
authors.initials: T
authors.lastname: Liu
authors.forename: Weiwei
authors.initials: W
authors.lastname: Cheng
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
mesh_terms: D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis; D051379:Mice; D016513:Mice, SCID; D010455:Peptides; D014183:Transplantation, Heterologous
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; C497483:CD44 protein, human; D006023:Glycoproteins; D018960:Hyaluronan Receptors; C000606023:PROM1 protein, human; D010455:Peptides; C000606024:Prom1 protein, mouse